人胰高血糖素樣肽-1作用機制 - Medchemexpress - MCE中國

1、Product Data SheetGLP-1(7-37)Cat. No.: HY-P0055CAS No.: 106612-94-6分式: CHNO分量: 3355.67Sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-GlySequence Shortening: HAEGTFTSDVSSYLEGQAAKEFIAWLVKG-R-G作靶點: Glucagon Receptor作通路:

2、GPCR/G Protein儲存式: Powder -80C 2 years-20C 1 yearIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 H2O : 30 mg/mL (8.94 mM; Need ultrasonic and warming)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 0.2980 mL 1.4900 mL 2.9800 mL5 mM 0.0596 mL 0.2980 mL 0.5960 mL10 mM 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，

3、請分裝保存，避免反復凍融造成的產品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內使，-20C 儲存時，請在 1 個內使。BIOLOGICAL ACTIVITY物活性 GLP-1(7-37)種腸道胰島素激素，可以增強葡萄糖誘導的胰島素分泌。體內研究GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clampincreased rate of glucose infusio

4、n in duces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and anInfusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulinconcentration relative to levels in rats infused with vehicle in

5、rats with maintained glucose concentration at 11 mM2.Page 1 of 2 www.MedChemEAnimal Model: Male Sprague-Dawley rats weighing 300 to 350 g with maintained plasma glucoseconcentration at 11 mM2.Dosage: 0.5, 5 or 50 pmol/min/kg.Administration: IV during the second hour of a 2-hour 11-mmol/L hyperglycem

6、ic clamp.Result: Produced a dose-related enhancement of the glucose-stimulated increase in plasmainsulin concentration and an increased rate of glucose infusion.Animal Model: Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variablerate for7 hours to maintain plasma glucose concen

7、tration at 11 mM2.Dosage: 5 pmol/min/kg.Administration: IV from 1 hour through 7 hours2.Result: Produced a sustained increase in plasma insulin concentration relative to levels in ratsinfused with vehicle.REFERENCES1. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region

8、 of GLP-1-7-37-NH2 for receptor interaction and cAMP production.European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004).2. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995Sep;44(9):1231-7.McePdfHeightCaution: Product has not been fully validated for medical applications. For research use